secwatch / observer
8-K filed May 19, 2026, 4:30 PM ET ticker VTGN CIK 0001411685
leadership confidence high sentiment neutral materiality 0.50

Vistagen appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer effective May 18, 2026

Vistagen Therapeutics, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Angel S. Angelov, M.D., MBA

Chief Medical Officer
VTGN · Vistagen Therapeutics, Inc.
Effective
2026-05-18
Filed
May 19, 2026, 4:30 PM ET
On May 18, 2026 (the “ Effective Date ”), Vistagen Therapeutics, Inc. (the “ Company ”) appointed Angel S. Angelov, M.D., MBA to serve as the Company’s Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Angel S. Angelov, M.D., MBA was appointed as Chief Medical Officer at Vistagen Therapeutics, Inc..

Action
appointed
Role
Chief Medical Officer
Exact text from the filing
On May 18, 2026 (the “ Effective Date ”), Vistagen Therapeutics, Inc. (the “ Company ”) appointed Angel S. Angelov, M.D., MBA to serve as the Company’s Chief Medical Officer.
View on SEC.gov

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001628280-26-036492
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.